Christopher Darr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christopher Darr has a total of 341 co-authors. Here are the top co-authors by number of shared publications:
- Viktor Grünwald
Interdisciplinary Genitourinary Oncology, Clinic for Internal Medicine (Tumor Research) and Clinic for Urology, West-German Cancer Center Essen, University Hospital Essen, Essen, Germany
29 shared publications - Katrin Schlack
22Department of Urology, University Hospital Münster, Münster, Germany
22 shared publications - Constantin Schwab
Institute of Pathology, University of Heidelberg, Heidelberg, Germany
21 shared publications - Jens Bedke
Department of Urology & Transplantation Surgery, Eva Mayr-Stihl Cancer Center Stuttgart, Klinikum Stuttgart, Stuttgart, Germany
21 shared publications - Manuel Ritter
Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany
21 shared publications - Marieta Toma
Institute of Pathology, University Hospital Bonn, Bonn, Germany
21 shared publications
Latest Publications
- Open Access
- 28 September 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF14
Integrating NECTIN4 Amplification with Membranous NECTIN4 Expression to Develop a Scoring System for Predicting Enfortumab Vedotin Response in Urothelial Carcinoma
Purpose: Enfortumab vedotin (EV) is standard therapy for metastatic urothelial carcinoma (mUC), yet the predictive relevance of Nectin cell adhesion molecule 4 (NECTIN4) expression—especially membranous versus cytoplasmic—remains unclear. In this study, we sought to extend previous findings on NECTIN4 gene amplification in parallel with a systematic subcellular evaluation of Nectin-4 expression. Experimental Design: We retrospectively analyzed 179 EV-treated patients with mUC. NECTIN4 amplification was assessed by fluorescence in situ hybridization (FISH) and Nectin-4 protein levels by immunohistochemistry (IHC). A four-tier membranous scoring algorithm (0, 1+, 2+, and 3+) adapted from the College of American Pathologists (CAP) HER2 gastric guidelines was benchmarked against H-score. We integrated amplification status with membranous staining to refine predictive stratification and compared associations with objective response rate (ORR) with those observed in EV-301 data. Results: Combining membranous and cytoplasmic compartments resulted in a median composite H-score of 260 (78.2% ≥ 150), closely matching Nectin-4 expression prevalence reported in EV-301 (median, 250; 82.6% ≥ 150). A ≥150 cutoff enriched for EV responders in both cohorts, with an ORR of 45.8% versus 20% (P = 0.001) in EV-301. High membranous expression based on the scoring (2+/3+) predicted response (ORR, 55.1% vs. 25.5%; P < 0.001), with longer progression-free survival [PFS; 7.1 vs. 2.9 months; hazard ratio (HR) = 0.45] and overall survival (OS; 12.3 vs. 6.9 months; HR = 0.57), whereas cytoplasmic expression lacked predictive value. NECTIN4-amplified tumors showed particularly favorable outcomes (PFS, 12.2 months; OS, 30.1 months). An integrated three-tier model—amplified, nonamplified/high-membranous, and nonamplified/low-membranous—yielded ORRs of 77.2%, 42.9%, and 26.1% and separated survival outcomes. Conclusions: Our Nectin-4 scoring system integrating NECTIN4 amplification with membranous Nectin-4 expression accurately predicts outcomes, supporting combined genomic and membranous assessment as complementary biomarkers for optimizing EV selection. See related article by YYY, p. XX .
- 28 September 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF14
Open AccessIntegrating NECTIN4 Amplification with Membranous NECTIN4 Expression to Develop a Scoring System for Predicting Enfortumab Vedotin Response in Urothelial Carcinoma
Purpose: Enfortumab vedotin (EV) is standard therapy for metastatic urothelial carcinoma (mUC), yet the predictive relevance of Nectin cell adhesion molecule 4 (NECTIN4) expression—especially membranous versus cytoplasmic—remains unclear. In this study, we sought to extend previous findings on NECTIN4 gene amplification in parallel with a systematic subcellular evaluation of Nectin-4 expression. Experimental Design: We retrospectively analyzed 179 EV-treated patients with mUC. NECTIN4 amplification was assessed by fluorescence in situ hybridization (FISH) and Nectin-4 protein levels by immunohistochemistry (IHC). A four-tier membranous scoring algorithm (0, 1+, 2+, and 3+) adapted from the College of American Pathologists (CAP) HER2 gastric guidelines was benchmarked against H-score. We integrated amplification status with membranous staining to refine predictive stratification and compared associations with objective response rate (ORR) with those observed in EV-301 data. Results: Combining membranous and cytoplasmic compartments resulted in a median composite H-score of 260 (78.2% ≥ 150), closely matching Nectin-4 expression prevalence reported in EV-301 (median, 250; 82.6% ≥ 150). A ≥150 cutoff enriched for EV responders in both cohorts, with an ORR of 45.8% versus 20% (P = 0.001) in EV-301. High membranous expression based on the scoring (2+/3+) predicted response (ORR, 55.1% vs. 25.5%; P < 0.001), with longer progression-free survival [PFS; 7.1 vs. 2.9 months; hazard ratio (HR) = 0.45] and overall survival (OS; 12.3 vs. 6.9 months; HR = 0.57), whereas cytoplasmic expression lacked predictive value. NECTIN4-amplified tumors showed particularly favorable outcomes (PFS, 12.2 months; OS, 30.1 months). An integrated three-tier model—amplified, nonamplified/high-membranous, and nonamplified/low-membranous—yielded ORRs of 77.2%, 42.9%, and 26.1% and separated survival outcomes. Conclusions: Our Nectin-4 scoring system integrating NECTIN4 amplification with membranous Nectin-4 expression accurately predicts outcomes, supporting combined genomic and membranous assessment as complementary biomarkers for optimizing EV selection. See related article by YYY, p. XX .
- Open Access
- 26 August 2026
- Published by Wiley in BJU International
- Vol. 138 (6) , 1092-1103
Sexual function after prostate cancer surgery or radiotherapy in an international registry
Objectives: Our objective was to evaluate patient‐reported sexual function (SF) outcomes and sexual aid use 12 months after curative treatment for prostate cancer (PC). Patients & Methods: This prospective registry‐based cohort study analysed men with localized or locally advanced PC enrolled in the TrueNTH Global Registry. Patients with baseline and 12‐month patient‐reported outcome measures after radical prostatectomy (RP), external beam radiotherapy (EBRT) ± androgen‐deprivation therapy (ADT), or brachytherapy (BT) were included. SF was assessed using the EPIC‐26 sexual function domain score (SFDS). Baseline and 12‐month EPIC‐26 SFDS were compared by treatment group, with additional analyses among RP patients examining outcomes by intent to nerve spare and sexual aid use. Linear regression, adjusted for age, National Comprehensive Cancer Network risk group, baseline SFDS, and intent to nerve spare was used to identify predictors of 12‐month SFDS among surgery patients. Results: Overall, 13 413 men were analysed (RP 85.2%, EBRT only 9.1%, EBRT+ADT 4.3%, BT 1.3%). SF declined significantly across all modalities. Median SFDS reduction was greatest after RP (−60.0%) and smallest after BT (−40.2%). At 12 months, poor or absent erectile function was reported by 63.6–91.8% of patients, highest after RP and EBRT+ADT. Sexual aid use increased after treatment but remained low overall. Given the retrospective design and non‐representative sites in an international registry setting, these findings should be interpreted as associational rather than causal because of the potential for unmeasured confounding and cross‐country heterogeneity in treatment selection. Conclusion: All curative PC treatments were associated with substantial deterioration in SF. These findings support enhanced pre‐treatment counselling and early integration of proactive management and structured sexual rehabilitation into survivorship care.
- 26 August 2026
- Published by Wiley in BJU International
- Vol. 138 (6) , 1092-1103
Open AccessSexual function after prostate cancer surgery or radiotherapy in an international registry
Objectives: Our objective was to evaluate patient‐reported sexual function (SF) outcomes and sexual aid use 12 months after curative treatment for prostate cancer (PC). Patients & Methods: This prospective registry‐based cohort study analysed men with localized or locally advanced PC enrolled in the TrueNTH Global Registry. Patients with baseline and 12‐month patient‐reported outcome measures after radical prostatectomy (RP), external beam radiotherapy (EBRT) ± androgen‐deprivation therapy (ADT), or brachytherapy (BT) were included. SF was assessed using the EPIC‐26 sexual function domain score (SFDS). Baseline and 12‐month EPIC‐26 SFDS were compared by treatment group, with additional analyses among RP patients examining outcomes by intent to nerve spare and sexual aid use. Linear regression, adjusted for age, National Comprehensive Cancer Network risk group, baseline SFDS, and intent to nerve spare was used to identify predictors of 12‐month SFDS among surgery patients. Results: Overall, 13 413 men were analysed (RP 85.2%, EBRT only 9.1%, EBRT+ADT 4.3%, BT 1.3%). SF declined significantly across all modalities. Median SFDS reduction was greatest after RP (−60.0%) and smallest after BT (−40.2%). At 12 months, poor or absent erectile function was reported by 63.6–91.8% of patients, highest after RP and EBRT+ADT. Sexual aid use increased after treatment but remained low overall. Given the retrospective design and non‐representative sites in an international registry setting, these findings should be interpreted as associational rather than causal because of the potential for unmeasured confounding and cross‐country heterogeneity in treatment selection. Conclusion: All curative PC treatments were associated with substantial deterioration in SF. These findings support enhanced pre‐treatment counselling and early integration of proactive management and structured sexual rehabilitation into survivorship care.
- Open Access
- 22 May 2026
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (5) , 102580
Assessment of Tumor Microenvironment Inflammatory Biomarkers in Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors
- 22 May 2026
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (5) , 102580
Open AccessAssessment of Tumor Microenvironment Inflammatory Biomarkers in Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors
- Open Access
- 19 January 2026
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 11
Histotype-specific incidence and survival of urothelial carcinoma—an analysis of the German North Rhine-Westphalia Cancer Registry
- 19 January 2026
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 11
Open AccessHistotype-specific incidence and survival of urothelial carcinoma—an analysis of the German North Rhine-Westphalia Cancer Registry
- Open Access
- 5 December 2025
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 51 (5) , 198-202
Predictors of Biochemical Recurrence in Patients with Positive Surgical Margin After Radical Prostatectomy
Objective: To investigate the predictors of biochemical recurrence (BCR) in patients with positive surgical margins (PSMs) after radical prostatectomy (RP). Methods: The data of patients who underwent open RP between 2003 and 2011 were reviewed. Only patients with PSM and negative lymph node invasion were considered for further analysis. Multivariable Cox regression analysis was performed to evaluate the correlation between clinicopathologic criteria and BCR. Results: Out of 116 patients, 80 (69%) developed BCR with a median (interquartile range [IQR]) time to recurrence of 19 (9-50) months. Median (IQR) time of follow-up in non-recurrent patients was 121 (47-148) months. The 5- and 10-year BCR-free survival rates were 43% and 28%, respectively. Complete data regarding margin parameters were available only for 98 patients, of which 71 (72%) developed BCR. Univariable analysis demonstrated that prostate volume (PV) (HR 0.97, 95% CI 0.95-0.99, P = .005), highest Gleason grade (GG) at the margin (HR 1.73, 95% CI: 1-2.83, P = .028 for GG 4-5 vs. 3), tumor GG group 2 (HR [Hazard Ratio] 2, 95% CI 1.09-3.94, P = .025) and 4-5 (HR 2.34, 95% CI 1-4.98, P = .028) were significant predictors of BCR. In multivariable analysis, only PV remained an independent predictor of BCR (HR 0.98, 95% CI 0.96-0.99, P = .03). Conclusion: In patients with PSM after RP, smaller prostates have a higher probability of BCR. Further studies are needed to investigate this association. The highest GG at the margin has important predictive accuracy and should be reported in the pathol ogy report. Cite this article as: Mahmuod O, Al-Nader M, Grevendieck A, et al. Predictors of biochemical recurrence in patients with positive surgical margin after radical prostatectomy. Urol Res Pract. 2025;51(5):198-202.
- 5 December 2025
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 51 (5) , 198-202
Open AccessPredictors of Biochemical Recurrence in Patients with Positive Surgical Margin After Radical Prostatectomy
Objective: To investigate the predictors of biochemical recurrence (BCR) in patients with positive surgical margins (PSMs) after radical prostatectomy (RP). Methods: The data of patients who underwent open RP between 2003 and 2011 were reviewed. Only patients with PSM and negative lymph node invasion were considered for further analysis. Multivariable Cox regression analysis was performed to evaluate the correlation between clinicopathologic criteria and BCR. Results: Out of 116 patients, 80 (69%) developed BCR with a median (interquartile range [IQR]) time to recurrence of 19 (9-50) months. Median (IQR) time of follow-up in non-recurrent patients was 121 (47-148) months. The 5- and 10-year BCR-free survival rates were 43% and 28%, respectively. Complete data regarding margin parameters were available only for 98 patients, of which 71 (72%) developed BCR. Univariable analysis demonstrated that prostate volume (PV) (HR 0.97, 95% CI 0.95-0.99, P = .005), highest Gleason grade (GG) at the margin (HR 1.73, 95% CI: 1-2.83, P = .028 for GG 4-5 vs. 3), tumor GG group 2 (HR [Hazard Ratio] 2, 95% CI 1.09-3.94, P = .025) and 4-5 (HR 2.34, 95% CI 1-4.98, P = .028) were significant predictors of BCR. In multivariable analysis, only PV remained an independent predictor of BCR (HR 0.98, 95% CI 0.96-0.99, P = .03). Conclusion: In patients with PSM after RP, smaller prostates have a higher probability of BCR. Further studies are needed to investigate this association. The highest GG at the margin has important predictive accuracy and should be reported in the pathol ogy report. Cite this article as: Mahmuod O, Al-Nader M, Grevendieck A, et al. Predictors of biochemical recurrence in patients with positive surgical margin after radical prostatectomy. Urol Res Pract. 2025;51(5):198-202.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
Supplementary Figure 1. Expression of membranous NECTIN-4 in UC histology subtypes in PRIM (A) and MET (B). (C) depicts differential NECTIN-4 expression during metastatic spread. Intergroup comparison was calculated by non-parametric Kruskal-Wallis test.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
Supplementary Figure 1. Expression of membranous NECTIN-4 in UC histology subtypes in PRIM (A) and MET (B). (C) depicts differential NECTIN-4 expression during metastatic spread. Intergroup comparison was calculated by non-parametric Kruskal-Wallis test.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data TS1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
Supplementary Table 1. Clinico-pathological characteristics of the UC progression PRIM-MET study cohort. BRA=brain metastasis; HEP=hepatic metastasis; LYM=non-locoregionary lymph node metastasis; OSS=bone metastasis; OTH= metastasis at other locations including soft tissue; PER=peritoneal metastasis; PUL=pulmonary metastasis.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data TS1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
Supplementary Table 1. Clinico-pathological characteristics of the UC progression PRIM-MET study cohort. BRA=brain metastasis; HEP=hepatic metastasis; LYM=non-locoregionary lymph node metastasis; OSS=bone metastasis; OTH= metastasis at other locations including soft tissue; PER=peritoneal metastasis; PUL=pulmonary metastasis.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data TS2 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
Supplementary Table 2. Baseline characteristics of the multicenter EV cohort.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data TS2 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
Supplementary Table 2. Baseline characteristics of the multicenter EV cohort.
- Open Access
- 14 April 2025
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 8
Effectiveness, toxicity and treatment adjustments of lenvatinib plus pembrolizumab in advanced renal cell carcinoma: a multicenter real-world analysis
- 14 April 2025
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 8
Open AccessEffectiveness, toxicity and treatment adjustments of lenvatinib plus pembrolizumab in advanced renal cell carcinoma: a multicenter real-world analysis
- Open Access
- 31 October 2024
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 26, e55148
Establishing Medical Intelligence—Leveraging Fast Healthcare Interoperability Resources to Improve Clinical Management: Retrospective Cohort and Clinical Implementation Study
Background: FHIR (Fast Healthcare Interoperability Resources) has been proposed to enable health data interoperability. So far, its applicability has been demonstrated for selected research projects with limited data. Objective: This study aimed to design and implement a conceptual medical intelligence framework to leverage real-world care data for clinical decision-making. Methods: A Python package for the use of multimodal FHIR data (FHIRPACK [FHIR Python Analysis Conversion Kit]) was developed and pioneered in 5 real-world clinical use cases, that is, myocardial infarction, stroke, diabetes, sepsis, and prostate cancer. Patients were identified based on the ICD-10 (International Classification of Diseases, Tenth Revision) codes, and outcomes were derived from laboratory tests, prescriptions, procedures, and diagnostic reports. Results were provided as browser-based dashboards. Results: For 2022, a total of 1,302,988 patient encounters were analyzed. (1) Myocardial infarction: in 72.7% (261/359) of cases, medication regimens fulfilled guideline recommendations. (2) Stroke: out of 1277 patients, 165 received thrombolysis and 108 thrombectomy. (3) Diabetes: in 443,866 serum glucose and 16,180 glycated hemoglobin A1c measurements from 35,494 unique patients, the prevalence of dysglycemic findings was 39% (13,887/35,494). Among those with dysglycemia, diagnosis was coded in 44.2% (6138/13,887) of the patients. (4) Sepsis: In 1803 patients, Staphylococcus epidermidis was the primarily isolated pathogen (773/2672, 28.9%) and piperacillin and tazobactam was the primarily prescribed antibiotic (593/1593, 37.2%). (5) PC: out of 54, three patients who received radical prostatectomy were identified as cases with prostate-specific antigen persistence or biochemical recurrence. Conclusions: Leveraging FHIR data through large-scale analytics can enhance health care quality and improve patient outcomes across 5 clinical specialties. We identified (1) patients with sepsis requiring less broad antibiotic therapy, (2) patients with myocardial infarction who could benefit from statin and antiplatelet therapy, (3) patients who had a stroke with longer than recommended times to intervention, (4) patients with hyperglycemia who could benefit from specialist referral, and (5) patients with PC with early increases in cancer markers.
- 31 October 2024
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 26, e55148
Open AccessEstablishing Medical Intelligence—Leveraging Fast Healthcare Interoperability Resources to Improve Clinical Management: Retrospective Cohort and Clinical Implementation Study
Background: FHIR (Fast Healthcare Interoperability Resources) has been proposed to enable health data interoperability. So far, its applicability has been demonstrated for selected research projects with limited data. Objective: This study aimed to design and implement a conceptual medical intelligence framework to leverage real-world care data for clinical decision-making. Methods: A Python package for the use of multimodal FHIR data (FHIRPACK [FHIR Python Analysis Conversion Kit]) was developed and pioneered in 5 real-world clinical use cases, that is, myocardial infarction, stroke, diabetes, sepsis, and prostate cancer. Patients were identified based on the ICD-10 (International Classification of Diseases, Tenth Revision) codes, and outcomes were derived from laboratory tests, prescriptions, procedures, and diagnostic reports. Results were provided as browser-based dashboards. Results: For 2022, a total of 1,302,988 patient encounters were analyzed. (1) Myocardial infarction: in 72.7% (261/359) of cases, medication regimens fulfilled guideline recommendations. (2) Stroke: out of 1277 patients, 165 received thrombolysis and 108 thrombectomy. (3) Diabetes: in 443,866 serum glucose and 16,180 glycated hemoglobin A1c measurements from 35,494 unique patients, the prevalence of dysglycemic findings was 39% (13,887/35,494). Among those with dysglycemia, diagnosis was coded in 44.2% (6138/13,887) of the patients. (4) Sepsis: In 1803 patients, Staphylococcus epidermidis was the primarily isolated pathogen (773/2672, 28.9%) and piperacillin and tazobactam was the primarily prescribed antibiotic (593/1593, 37.2%). (5) PC: out of 54, three patients who received radical prostatectomy were identified as cases with prostate-specific antigen persistence or biochemical recurrence. Conclusions: Leveraging FHIR data through large-scale analytics can enhance health care quality and improve patient outcomes across 5 clinical specialties. We identified (1) patients with sepsis requiring less broad antibiotic therapy, (2) patients with myocardial infarction who could benefit from statin and antiplatelet therapy, (3) patients who had a stroke with longer than recommended times to intervention, (4) patients with hyperglycemia who could benefit from specialist referral, and (5) patients with PC with early increases in cancer markers.